Vedolizumab (VDZ) is an established biological therapy for ulcerative colitis (UC) but may have a relatively slow onset of action during induction. VSL#3TM is a high‑potency, multi‑strain probiotic proposed to modulate the gut microbiota and intestinal immune responses. The authors conducted a preliminary, real‑world single‑arm study to evaluate whether combining VSL#3TM with vedolizumab is associated with earlier or improved clinical outcomes and acceptable safety in patients with active UC.
This was a retrospective collection of clinical data from patients with active UC who received VSL#3TM combined with vedolizumab for at least 12 weeks at the Second Affiliated Hospital of Zhejiang University School of Medicine in China. The inclusion window for treatment was January 2023 through December 2024. The study was registered (ClinicalTrials.gov identifier NCT06609447) and received ethics approval (Ethics Committee approval no. YJ2024-0965). The primary endpoints were clinical response rates at weeks 6 and 12. Secondary endpoints included clinical remission, changes in the inflammatory bowel disease questionnaire (IBDQ) score as a quality‑of‑life measure, and safety assessment. Clinical response and remission were evaluated using PRO2 criteria and the Full Mayo Score where available. The source reports patient counts for key endpoints and describes the handling of Clostridioides difficile (CDI) testing results.
By PRO2 criteria, the study reports clinical response in 82.4% (14/17) of patients at 6 weeks and in 100.0% (17/17) at 12 weeks. Clinical remission by PRO2 at week 12 was reported in 58.8% (10/17). When assessed by Full Mayo Score, week‑12 clinical response was 68.8% (11/16) and clinical remission was 50.0% (8/16). The authors note these response and remission rates appeared numerically higher than those reported in published historical vedolizumab monotherapy studies, but emphasize that direct comparison is limited by the single‑arm, nonrandomized design.
Quality of life, measured with the IBDQ, improved over the 12‑week period. Mean IBDQ score increased from 157.3 at baseline to 174.5 at week 12; this change was statistically significant in the report (p < 0.001). The improvement in IBDQ aligns with the reported clinical response and remission rates but the study did not link specific microbiota or immunologic biomarkers to the observed clinical or quality‑of‑life changes.
The combination of VSL#3TM and vedolizumab was reported as well tolerated in this cohort, with no serious adverse events recorded. Nonserious adverse events recorded included fatigue in 1/17 patients (5.9%), borborygmus in 2/17 (11.8%), and arthralgia in 1/17 (5.9%). No additional safety signal or unexpected toxicity was reported in the source text.
Among patients with baseline history of CDI positivity, all three were reported as negative for both toxin and antigen at 12 weeks. The authors note one patient who was toxin‑positive had received anti‑CDI antibiotic therapy; the report does not provide further microbiologic or temporal detail beyond these summary results.
The authors explicitly describe this work as a preliminary, retrospective, single‑arm real‑world study. As such, the findings are subject to important limitations: absence of a concurrent control group, small sample size (denominators reported for endpoints were 16–17 patients), potential selection and ascertainment biases, and lack of direct mechanistic assessment (no microbiome or immune profiling was reported). Although response rates were compared qualitatively to historical vedolizumab monotherapy data and appeared numerically higher, the source cautions against definitive comparative conclusions due to design limitations. Data supporting the findings are not publicly available because of patient privacy; the source indicates de‑identified data can be requested subject to institutional and ethical approvals.
In this single‑center, real‑world cohort the combination of VSL#3TM and vedolizumab was associated with high early clinical response rates by PRO2 (82.4% at week 6; 100% at week 12), meaningful improvements in IBDQ score by week 12, and no serious adverse events reported. The authors propose that complementary effects on the gut microbiota and intestinal immune responses may underlie the observed clinical improvements, but those mechanisms were not assessed in this dataset. They recommend that larger prospective randomized controlled trials are needed to confirm whether adding VSL#3TM to vedolizumab induction improves clinical outcomes in active UC.
Ethical and administrative details reported in the source include institutional ethics approval (YJ2024-0965), trial registration (NCT06609447), and the statement that all relevant patient consents and reporting guidelines were followed. Funding sources declared in the source text are listed, and no competing interests were declared by the authors.